

Effects of Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) on insulin secretion and energy balance in human obesity and diabetes

Submission date

29/09/2006

Recruitment status

No longer recruiting

☐ Prospectively registered

☐ Protocol

Registration date

29/09/2006

Overall study status

Completed

☐ Statistical analysis plan

☒ Results

Last Edited

28/09/2011

Condition category

Nutritional, Metabolic, Endocrine

☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr L R Ranganath

Contact details

Dept. of Clinical Chemistry
Royal Liverpool University Hospital
Prescot Street
Liverpool
United Kingdom
L7 8XP
+44 0151 706 4197
lrang@liv.ac.uk

Additional identifiers

Protocol serial number

N0207174689

Study information

Scientific Title

Study objectives

1. Are both GIP and GLP-1 necessary for optimal insulin secretion in healthy and diabetic subjects?
2. Do both GIP and GLP-1 have an effect on energy balance and appetite?

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Nutritional, Metabolic, Endocrine: Diabetes

Interventions

At the baseline assessment visit, eligibility will be confirmed, subjects will be weighed, height recorded, and waist circumference measured. Body composition will be measured by electrical bio impedance (Tanita 310). Thereafter, 4 half day studies are required for measurements of insulin secretion during infusion of GLP-1 alone, GIP alone, GLP-1 and GIP together and placebo. Because GLP-1 and GIP augment glucose-stimulated insulin secretion will be determined in response to co-infusion of 10% glucose during each experiment by serial blood sampling. Throughout these experiments, resting metabolic rate will be measured at baseline and then hourly (for postprandial thermogenesis) by indirect calorimetry, using the Deltatrack II system. Effects on hunger and satiety will be determined from concomitant visual analogue hunger scores taken at baseline and then hourly. Ad libitum food intake will be assessed with test meal at lunchtime. The studies will be completed once lunch is consumed. A total of 48 studies will be undertaken. GLP-1/GIP peptides: GLP-1 and GIP has been obtained from Polypeptide Laboratories (Germany) and sterile-filtered by Stockport Pharmaceuticals (Stebbing Hill Hospital, Stockport). In preliminary work with synthetic peptides in non diabetic subjects we have found infusion of GLP-1 at rates of 1pmol/kg/min to be well tolerated without side effects, and to result in highly significant and sustained elevations in plasma insulin and C peptide concentrations. Steady states of insulin are reached after 60 minutes of infusion at this rate. Glucose profiles in plasma were maintained in the euglycaemic range during the combined infusion of dextrose and GLP-1 (unpublished).

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulintropic polypeptide (GIP)

Primary outcome(s)

Role of GIP and GLP-1 in diabetes and obesity

Key secondary outcome(s))

Not provided at time of registration

Completion date

01/09/2006

Eligibility

Key inclusion criteria

Obese male subjects between age 20-60 years will be recruited by advertisement and by invitation of eligible patients who have already undergone glucose tolerance testing. This is a pilot study and will involve the following groups. 6 lean (BMI 20-25 kg/m²) subjects with normal glucose tolerance and 6 obese (BMI >30 kg/m²) type-2 diabetic patients on treatment with diet alone. Eligible subjects will be asked to provide informed written consent, and studies will be undertaken in accordance with the Declaration of Helsinki.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Male

Key exclusion criteria

Any co-morbid conditions requiring drug therapy that cannot be discontinued, any regular drug treatment that cannot be discontinued, any diseases of the heart, lungs, liver, gut or endocrine glands, alcoholism, eating disorder, and for the diabetic group - poorly controlled diabetes (defined as HbA1c >8.0% for the purposes of this study)

Date of first enrolment

01/09/2004

Date of final enrolment

01/09/2006

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Dept. of Clinical Chemistry

Liverpool

United Kingdom

L7 8XP

Sponsor information

Organisation

Record Provided by the NHSTCT Register - 2006 Update - Department of Health

Funder(s)

Funder type

Government

Funder Name

Royal Liverpool and Broadgreen University Hospitals Trust (UK), RLUH R&D Trust Fund,

Funder Name

NHS R&D Support Funding.

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2009		Yes	No

